Back to Sectors

DCOY

Decoy Therapeutics Inc.
8 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 3/31/2026 | acquisitionBEARISH | 90% | 3/31/2026 | dilution riskBEARISH | 60% | 3/31/2026 | margin compressionBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeBEARISH | 70% | 5/8/2026 | margin compressionNEUTRAL | 50% | 5/8/2026 | capital raiseBULLISH | 60% | 5/8/2026 | management changeMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bearishMay 8

Net loss increased to $2.2M due to higher R&D and G&A costs.

margin compression
70%
neutralMay 8

Company indicates a need for additional capital to fund operations through 2027.

capital raise
50%
bullishMay 8

Successful merger and rebranding to Decoy Therapeutics to focus on AI-peptide platform.

management change
60%
bullishMar 31

Completed merger with Legacy Decoy to acquire the IMP³ACT AI platform.

acquisition
70%
bearishMar 31

Going-concern warning and critical cash shortage necessitate future equity raises.

dilution risk
90%
bearishMar 31

Pre-revenue status with significant net losses and high R&D burn.

margin compression
60%

Filing History

10-QMay 8, 2026

The Q1 2026 filing captures Decoy Therapeutics at a critical inflection point, balancing a high-upside technological pivot against a deteriorating liquidity profile. The merger with Legacy Decoy has successfully consolidated the IMP3ACT platform, but the transition has accelerated cash burn and left the company with a narrow window to achieve a value-unlocking event. The shift in R&D spending confirms that management is all-in on the AI-peptide strategy, effectively abandoning previous clinical paths in favor of the D-MAV program. For investors, the trade-off is now stark: the potential for a paradigm shift in peptide conjugate discovery versus the very real risk of insolvency or extreme dilution. The company's ability to maintain its Nasdaq listing and secure additional non-dilutive funding will be the primary indicators of survival. The upcoming window for IND filings in 2027 represents the ultimate catalyst, but the path there requires a level of financial stability that is not currently evident in the unaudited balance sheet.

10-KMar 31, 2026

The 10-K reveals a company at a critical crossroads, balancing a sophisticated technological leap against an existential financial struggle. The integration of the IMP³ACT platform and the shift toward pan-coronavirus therapeutics provide a clear, high-upside vision, but the balance sheet remains the primary headwind. The company has successfully navigated immediate Nasdaq delisting threats through reverse splits and compliance plans, yet the underlying need for substantial capital to reach the 2027 IND filing remains acute. Investors are essentially betting on a binary outcome: whether the AI-accelerated pipeline can produce a proof-of-concept success in human trials before the cash runway expires in late 2026. While the non-dilutive grant support provides a temporary cushion, the lack of revenue and the high cost of clinical scaling create a high-risk environment. The overall impact of the filing is a transition from a legacy small-molecule entity to a platform-based biotech, but one that is currently operating on a razor-thin margin of survival.